Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Candida Albicans in the Severity of Multiple Sclerosis Publisher Pubmed



Saroukolaei SA1 ; Ghabaee M1 ; Shokri H2 ; Badiei A3 ; Ghourchian S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Neurology Department, Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Faculty of Veterinary Medicine, Amol University of Special Modern Technologies, Amol, Iran
  3. 3. Department of Pathology, University of Otago, Christchurch, New Zealand
  4. 4. Medical Internship, Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Mycoses Published:2016


Abstract

The purpose of this study was to compare the specific activity of proteinase A in Candida albicans (C. albicans) between multiple sclerosis (MS) patients and controls. A total of 135 and 100 C. albicans strains were isolated from superficial surfaces of MS patients and healthy controls. Analytical models (regression and neural network) were applied to predict the severity of MS considering specific enzyme activity (SEA) and other factors which affect the expanded disability status scale (EDSS). The SEA of C. albicans in MS patients (3466.95 ± 277.25 μmol min−1 mg−1) was significantly more than that of healthy controls (1108.98 ± 294.51 μmol min−1 mg−1) that was confirmed by regression model (P < 0.001). The SEA had a positive correlation with the severity of MS (P < 0.001, r = 0.65). Analytical models showed that SEA played the most important role (among all included factors that affect on EDSS) in the severity of MS. The SEA of C. albicans in MS patients was significantly more than the healthy controls. The results suggest that the level of SEA of proteinase A and probably the capacity of C. albicans isolates to invade the host tissue is associated with the severity of MS. © 2016 Blackwell Verlag GmbH
Other Related Docs
9. Fluoxetine for Multiple Sclerosis, Cochrane Database of Systematic Reviews (2018)
11. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
15. Blood Lead Levels and Multiple Sclerosis: A Case-Control Study, Multiple Sclerosis and Related Disorders (2019)
17. Early-Onset Multiple Sclerosis: Reports of 300 Patients From Iran, Journal of Pediatric Neurosciences (2018)
23. Prevalence and Predictors of Dysphagia in Iranian Patients With Multiple Sclerosis, Medical Journal of the Islamic Republic of Iran (2017)